As the FDA halts the use of Regeneron and Eli Lilly treatments for COVID-19, the supply remains scarce of a newer drug from GlaxoSmithKline and Vir Biotechnology.
Original article: https://www.reviewjournal.com/local/local-las-vegas/new-drug-for-treatment-of-covid-remains-scarce-in-las-vegas-2519201/
